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Peritoneal tissue-resident macrophages are
metabolically poised to engage microbes using
tissue-niche fuels
Luke C. Davies 1,2, Christopher M. Rice2, Erika M. Palmieri2, Philip R. Taylor 1, Douglas B. Kuhns3
& Daniel W. McVicar2
The importance of metabolism in macrophage function has been reported, but the in vivo
relevance of the in vitro observations is still unclear. Here we show that macrophage
metabolites are deﬁned in a speciﬁc tissue context, and these metabolites are crucially linked
to tissue-resident macrophage functions. We ﬁnd the peritoneum to be rich in glutamate, a
glutaminolysis-fuel that is exploited by peritoneal-resident macrophages to maintain
respiratory burst during phagocytosis via enhancing mitochondrial complex-II metabolism.
This niche-supported, inducible mitochondrial function is dependent on protein kinase C
activity, and is required to ﬁne-tune the cytokine responses that control inﬂammation. In
addition, we ﬁnd that peritoneal-resident macrophage mitochondria are recruited to phago-
somes and produce mitochondrially derived reactive oxygen species, which are necessary for
microbial killing. We propose that tissue-resident macrophages are metabolically poised
in situ to protect and exploit their tissue-niche by utilising locally available fuels to implement
speciﬁc metabolic programmes upon microbial sensing.
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T issue-resident macrophages (TRMØ) are tissue-specialisedimmune sentinels, which have key functions in homo-eostasis and inﬂammation1, 2. Like many TRMØ, perito-
neal TRMØ (pTRMØ) are not originally derived from
monocytes, but rather from embryonic progenitors seeded into
tissues before birth, with the populations maintained by local
proliferation3–6. These cells exist in complex environments and
do not ﬁt traditional polarisation categories, such as LPS and
interferon-γ stimulated pro-inﬂammatory (M1) and interleukin-4
stimulated anti-inﬂammatory (M2)2, 7. It has been shown that
tissue-niche environments can govern cell phenotype via epige-
netic programming8, 9. The precise factors responsible for this
in situ programming are largely uncategorised, although perito-
neal retinoic acid can induce Gata6 expression10 to dictate
pTRMØ phenotype10–12. However, the metabolic repertoire of
in situ environments are largely unknown, and it is likely that
other metabolites will govern resident cell functions in their
respective tissues2.
There has been resurgent interest in metabolic control of cel-
lular function, particularly in immunology13–15. In bone marrow-
derived macrophages (BMDM), M1 macrophage differentiation
in vitro and functions, including cytokine production, are
dependent on glucose and glutamine metabolism, whereas the
M2 phenotype reportedly relies on fatty acid oxidation for oxi-
dative phosphorylation (OXPHOS), and on glutamine for protein
modiﬁcations15, 16. However, M2 differentiation itself does not
require long-chain fatty acid oxidation17, 18. By contrast, little is
known about TRMØ metabolism, or which fuels are available in
tissue-niches that govern cell function2.
Macrophage biology encompasses common and tissue-niche
functions. For example, pTRMØ invade peritoneal organs and
facilitate repair19, supporting their physiological importance.
However, TRMØ are also the front-line immune sentinels that
possess primary macrophage functions including phagocytosis
and respiratory burst20. TRMØ express a repertoire of pattern-
recognition receptors, including Dectin-121, mannose receptor
and multiple toll-like receptors. These receptors engage microbes
to promote phagocytosis and assembly of NADPH oxidase
(NOX) 2 that supports oxidative respiratory burst22. Although
respiratory burst and the related signalling mechanisms are
understood in neutrophils, the metabolic requirements of
respiratory burst are not clear in TRMØ.
Here our results link the availability of peritoneal fuels and
requirements for pTRMØ metabolic processes that sustain
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Fig. 1 Peritoneal tissue-resident macrophages are highly oxidative and are fuelled by glutamine. a Heat-map showing the log10 difference from the average
metabolite peak areas from gas chromatography-mass spectrometry, which are associated with the citric acid cycle from peritoneal tissue-resident
macrophages (pTRMØ, Res) and bone marrow-derived macrophages (BMDM). Data show 3–6 independent samples per group analysed by two-way
ANOVA (interaction< 0.0001) with Sidak’s post-tests. b Schematic showing a simpliﬁed metabolic pathway detailing readouts for extracellular
acidiﬁcation rate (ECAR), oxygen consumption rate (OCR) and drugs, which inhibit these pathways, the red oval indicates the mitochondria. c Graph
showing representative Seahorse mitochondrial stress tests, O= oligomycin (1.26 μM), F= FCCP (0.67 μM), R/AA= Rotenone (0.2 μM) + antimycin A (1
μM). d Bar graphs showing quantiﬁed protein-normalised ECAR and mitochondrial OCR from stress tests in c, combination of the two OCR parameters
represents the maximum mitochondrial capacity. Data (n= 3 separate wells per group) represent three experiments, OCR data were analysed by paired
two-way ANOVA (interaction p< 0.0001) with Sidak’s post-tests for the difference between pTRMØ and BMDM (reserve/ maximal mitochondrial
capacity) or by Student’s t-test (ECAR). e Bar graph depicting the ratio of mitochondrial 16s deoxyribonucleic acid (DNA) vs β-actin DNA in three
independent samples, data was not signiﬁcant by Student’s t-test. f Bar graph showing the drop in maximum decoupled mitochondrial OCR after addition of
drugs or withdrawal of fuels. Glucose dependence was assessed using 2-deoxyglucose (2-DG, 100mM), pyruvate using UK-5099 (20µM), a mitochondrial
pyruvate transport inhibitor, long-chain fatty acids by etomoxir (100 μM) and glutamine by 1 h starvation before reintroduction of glutamine (2 mM) or
control media. g Stacked bar graph showing a breakdown of the effects of different metabolic fuels on maximum mitochondrial capacity from f. Data f and
g (n= at least 3 separate wells per group) represent at least two experiments, and were analysed by two-way ANOVA ((G) interaction p= 0.02; (F)
interaction p= 0.056, cell p= 0.017, fuel p< 0.0001) with Sidak’s post-tests. All error bars denote mean± SEM
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02092-0
2 NATURE COMMUNICATIONS |8:  2074 |DOI: 10.1038/s41467-017-02092-0 |www.nature.com/naturecommunications
respiratory burst. Resting pTRMØ are resistant to nutrient
depletion and have very little basal mitochondrial complex-II
(CII) activity. However, upon phagocytosis or metabolic stress,
pTRMØ utilise peritoneal metabolites to promote an enhance-
ment in glutaminolysis-fuelled CII metabolism that facilitates
respiratory burst required for microbial control and immune
function.
Results
PTRMØ have a substantial glutamate-fuelled mitochondrial
reserve. The majority of MØ research has been performed using
cultured cell lines and/or in vitro-derived BMDM. Accordingly,
precise mechanisms of how cells meet metabolic demands in vivo
remain unknown, making it critical to assess cell function in
conjunction with tissue-niche metabolites. The peritoneum con-
tains pTRMØ that are readily recovered without disruptive tissue
digestion, limiting alterations of in vivo-characteristics. We per-
formed gas chromatography-time-of-ﬂight metabolite analysis to
determine metabolic differences between macrophage colony
stimulating factor (M-CSF)-derived BMDM, the standard model
for macrophage functional analysis, and pTRMØ. Analysis
revealed a stark contrast, with many metabolites having statisti-
cally signiﬁcant differences (Two-way ANOVA post-tests p<
0.05) (Supplementary Fig. 1; Supplementary Data 1); however,
unbiased ingenuity pathway analysis (IPA) described enrichment
of tri-carboxylic acid (TCA) cycle-associated metabolites (Fig. 1a)
and lower amino acids in pTRMØ compared to BMDM (Sup-
plementary Fig. 1). Given these differences, we next compared
their RNA expression. RNA-sequencing revealed expected con-
trasts in gene expression, although surprisingly, IPA analysis did
not identify metabolic pathways as differentially regulated (Sup-
plementary Fig. 2). However, there were statistically signiﬁcant
differences in many metabolic genes (Limma-Voom-paired tests,
p< 0.05). This involved alternate expression of genes within the
same metabolic pathways, including different isoform expression
between the populations (Supplementary Fig. 3); explaining the
lack of IPA identiﬁcation. Together, these data support that
pTRMØ may have greater mitochondrial activity than BMDM
and perhaps deplete amino acids to support this. To assess
mitochondrial function, we quantiﬁed oxygen consumption rates
(OCR) during mitochondrial stress tests (Fig. 1b, c). Interestingly,
basal-OCR was comparable, however maximal mitochondrial
capacity was greater in pTRMØ (Fig. 1c, d), despite similar
mitochondrial quantiﬁcation (Fig. 1e). Accordingly, we analysed
mitochondrial volume in individual MØs (Supplementary
Movies 1–4). Mitochondrial morphology, volumes and numbers
were heterogeneous (Supplementary Fig. 4a), although on average
pTRMØ had fewer, but larger mitochondrial networks (Supple-
mentary Fig. 4b), resulting in similar total mitochondrial volumes
(Supplementary Fig. 4c). Collectively, this demonstrates that
pTRMØ have similar mitochondrial volume but higher OXPHOS
during metabolic stress, indicating greater mitochondrial efﬁ-
ciency23. Furthermore, pTRMØ exhibited higher extracellular
acidiﬁcation rates (ECAR), an indicator of glycolytic activity
(Fig. 1b, d).
OXPHOS is primarily fuelled from three sources: fatty acid
oxidation, glycolysis or glutaminolysis. We sought to establish
which fuels were used in maintenance of MØ mitochondrial
function using inhibitors and fuel deprivation (Fig. 1b). Basal-
OCRs of pTRMØ were resistant to nutrient stress, previously
attributed to an internal pool of stored metabolites24. However,
upon mitochondrial decoupling, the dependence of maximal
OCR on metabolic pathways could be interrogated. Despite
different origins, BMDM and pTRMØ display similar fuel
dependence, although pTRMØ required less glucose-derived
pyruvate (Fig. 1f, g). Together, these data demonstrate that
pTRMØ have approximately double the mitochondrial capacity
of BMDM, which is primarily dependent on glutamine and fatty
acids.
Subsequently, we investigated whether peritoneal metabolites
can support pTRMØ mitochondria. Indeed, peritoneal ﬂuid
augmented maximal OCR (Fig. 2a), demonstrating that perito-
neal fuels support pTRMØ mitochondrial function. To identify
speciﬁc fuels, we performed gas chromatography-time-of-ﬂight
metabolomic analysis on peritoneal ﬂuid. Serum supplies
metabolic fuels (such as glucose) from digestion to the body
including the peritoneum. Therefore, to test whether speciﬁc
metabolites might be enriched in the peritoneum compared to
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Fig. 2 Peritoneal tissue-resident macrophage mitochondria can be fuelled through abundant peritoneal glutamate. a Bar graph showing the effect of
5× diluted peritoneal ﬂuid (1 mM glucose media lavage followed by cell and protein depletion) in comparison to 1 mM glucose media on mitochondrial
parameters in peritoneal tissue-resident macrophages. Data were from one experiment (n= 5–6 separate wells per group) and analysed by paired two-way
ANOVA (interaction p< 0.0001) with Sidak’s post-tests. b Heat-map showing the log10 difference from the average metabolite peak areas from gas
chromatography-mass spectrometry analysis of the most enriched amino acids in peritoneal lavage ﬂuid and the fatty acids in blood serum, glucose and
glutamine act as a reference. Data show ﬁve independent samples that were analysed by two-way ANOVA (interaction p< 0.0001) with Sidak’s post-
tests. c Stacked graph detailing the addition of glutamine (Q, 0.25 mM) and glutamate (0.5 mM) to peritoneal tissue-resident macrophages and resulting
changes in mitochondrial parameters. Data are from the same experiment as a, but increases in mitochondrial function after glutamate and Q represent
three independent experiments, data were analysed by two-way ANOVA (interaction p< 0.0001), Sidak’s post-tests are indicated within the bars for
parameters vs 1 mM glucose and above representing the synergistic effect of glutamate and Q. All error bars denote mean± SEM
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blood, we directly compared metabolite levels. Indeed, our
analysis revealed many metabolites that were relatively enriched
in serum or peritoneum (Supplementary Fig. 5; Supplementary
Data 2). IPA analysis conﬁrmed multiple pathways were distinct
including fatty and amino acids, which were elevated in serum
and peritoneum respectively (Supplementary Fig. 5). Among the
most enriched amino acids in the peritoneum (Fig. 2b), we
identiﬁed the neurotransmitter N-acetyl aspartate (NAA); a
substrate for the pTRMØ-speciﬁc enzyme aspartoacyclase (Aspa
gene)12. Moreover, glutamate, was greatly enriched in the
peritoneum (Fig. 2b), although glutamine, the most abundant
amino acid in serum, was comparable. Glutamate, can fuel
glutaminolysis for anaplerotic replenishment of the TCA cycle
(Fig. 1b), suggesting importance in control of pTRMØ OXPHOS.
Glutamate, like glutamine, effectively fuelled maximal OCR in
pTRMØ and synergised with glutamine to enhance mitochon-
drial function (Fig. 2c). Collectively, these data show that
peritoneal fuels can support the substantial mitochondrial
function in pTRMØ. Glutamate, together with other amino acids
such as glutamine, would enable maximum mitochondrial
function in situ. Further, glutamine availability only limited
decoupled OCR, demonstrating that pTRMØ become more
dependent on glutaminolysis during stress.
PTRMØ utilise glutaminolysis to maintain respiratory burst.
We investigated whether peritoneal-supplied, glutaminolysis-
fuelled metabolism was important for a primary function of
TRMØ—respiratory burst. We monitor respiratory burst to
zymosan particles using OCR. These particles, but not soluble-
zymosan components or LPS, can initiate a protracted 4–6 h
respiratory burst in pTRMØ (Fig. 3a, b) demonstrating that
particle uptake may be necessary. Other ligands, including uric
acid crystals, N-Formylmethionyl-leucyl-phenylalanine (fMLF),
Pam3CSK4, R848, apoptotic thymocytes and Saccharomyces cer-
evisiae (S. cerevisiae) also trigger OCR increases (Supplementary
Fig. 6a), although at lower magnitudes than zymosan. Therefore,
we used zymosan-elicited OCR as tool to examine fuelling
requirements for pTRMØ respiratory burst. Absence of glutamine
or glucose did not affect zymosan phagocytosis in pTRMØ
(Fig. 3c). However, zymosan-elicited OCR required glutamine
and glucose to reach maximum intensity (Fig. 3d). The lower
magnitude OCR increases seen with other ligands was also
dependent on glutamine (Supplementary Fig. 6b). Glucose-
dependent increase in ECAR was also recorded in response to
zymosan (Fig. 3d). Inhibition of glycolysis and the pentose
phosphate pathway (PPP) using 2-deoxyglucose (2-DG) and
dehydroepiandrosterone (DHEA) conﬁrmed the requirement for
glucose metabolism (Fig. 3e), supporting that these pathways
maintain the supply of ATP and/or NADPH25. Long-chain fatty
acids were not a major requirement, and glutaminase inhibitors
conﬁrmed glutamine’s effect was attributable to catabolism
(Fig. 3f, g). Respiratory burst was also enhanced by glutamate,
further supporting a requirement for anaplerosis (Fig. 3h).
However, glutamate alone was unable to fully reconstitute the
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Fig. 3 Peritoneal tissue-resident macrophages enhance their respiratory burst with glutaminolysis. a Line graph showing oxygen consumption rate (OCR) in
peritoneal tissue-resident macrophages (pTRMØ). Arrow= zymosan (50 μg/ml), LPS (100 ng/ml) or control. b OCR changes in pTRMØ with washed
particle- or soluble-zymosan components. Data were analysed by Student’s t-test. c Quantiﬁcation of pTRMØ uptake of pHrodo zymosan (50 μg/ml,1 h).
G= glucose (25 mM), Q= glutamine (2 mM). Data were not signiﬁcant by one-way ANOVA (p= 0.0756) with Tukey’s post-tests. d OCR or extracellular
acidiﬁcation rate (ECAR) vs time in pTRMØ. Cells were starved from glutamine (Q) and cultured± glucose before addition of Q or control (grey arrow).
Zymosan= black arrow. Peak burst is quantiﬁed in the chart and analysed by one-way ANOVA (p< 0.0001), signiﬁcant Tukey’s post-tests for Q addition
are shown. e Graph showing the total oxygen consumption of pTRMØ after zymosan, quantiﬁed from OCR vs time (as in d), in the presence of 2-
deoxyglucose (2-DG, 100mM), dehydroepiandrosterone (DHEA,100 μM) or vehicle. Data were analysed by Student’s t-test. f Graph showing the
percentage oxygen consumption of pTRMØ after zymosan in the presence of etomoxir (50 μM) or vehicle. Data are pool of two experiments (n= 6–7) and
were analysed by two-way ANOVA (interaction p= 0.376, etomoxir p= 0.2588). g Relative total oxygen consumption after zymosan of pTRMØ pre-
treated with glutaminolysis inhibitors bis-phenylacetamido-thiadiazolyl-ethyl sulphide (BPTES, 15 μM) and diazo-oxo-norleucine (DON, 10mM), in the
presence or absence of Q. Data were analysed by two-way ANOVA (interaction p= 0.0536) with Sidak’s post-tests. h Total oxygen consumption after
zymosan of pTRMØ in the presence or absence of Q (4mM) or glutamate (4mM). Data were analysed by one-way ANOVA (p< 0.0001) with Tukey’s
post-tests. i Human monocytes were pre-cultured for 48 h with recombinant human M-CSF (50 ng/ml) and interferon-γ (10 ng/ml). Oxygen consumption
was quantiﬁed as in d and shows six separate wells per group pooled from two experiments, analysed by two-way ANOVA (interaction p= 0.1231), the ***
depicts the signiﬁcant effect of Q (p= 0.0009). Data (a–e, g, h) represent two experiments with at least three separate wells per group. All error bars
denote mean± SEM
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glutamine deprived respiratory burst, indicating different import
mechanisms or efﬁciencies.
Collectively, these data demonstrate that respiratory burst in
pTRMØ can be supported by locally enriched peritoneal
glutamate and complemented by glutamine. Accordingly, the
respiratory burst of human monocytes was also glutamine-
dependent (Fig. 3i), indicating that macrophage metabolic
programmes are not species-speciﬁc.
Neutrophil respiratory burst is glutamine-independent. The
glutamine requirement for oxidative burst in pTRMØ was sur-
prising, considering the glucose dependency of neutrophils25,
another professional phagocyte. Respiratory burst of neutrophils
was more acute than pTRMØ (Fig. 4a), despite similar levels of
zymosan phagocytosis (Fig. 4b), indicating that neutrophils initiate,
but do not sustain respiratory burst. Neutrophils, unlike pTRMØ,
do not require glutamine to reach their peak burst, but were wholly
dependent on glucose (Fig. 4c, d) through glycolysis (Fig. 4e). An
increase in glucose-dependent ECAR was also recorded (Fig. 4d).
Collectively, these data demonstrate that in contrast to neutrophils,
pTRMØ are pre-programmed to employ additional peritoneal fuels
to augment respiratory burst with glutaminolysis.
PTRMØ respiratory burst is enhanced by CII metabolism.
Respiratory burst was originally appreciated as a rapid increase in
oxygen consumption in neutrophils in response to pathogens, but
was redeﬁned as oxidase-dependent free radical generation26–28.
Unlike neutrophils29, pTRMØ have substantial basal OXPHOS
(Fig. 5a) that could contribute to detected OCRs. Therefore, a
mitochondrial stress test was performed during zymosan-induced
pTRMØ respiratory burst to precisely dissect OCR and evaluate
potential mitochondrial components. Unexpectedly, OCR during
zymosan-induced respiratory burst was primarily attributable to
increases in basal mitochondrial parameters (Fig. 5b) rather than
additional oxidase activity. However, maximal mitochondrial
capacity was unchanged (Fig. 5c), demonstrating that pTRMØ
have the same mitochondrial capacity regardless of stimulation,
but instead engage reserve mitochondrial capacity in response to
zymosan challenge. Accordingly, a NOX inhibitor had little effect
on zymosan-induced pTRMØ oxygen consumption, as opposed
to neutrophil which was ablated (Fig. 5d, e).
Subsequently, we dissected this unique mechanism using
speciﬁc inhibitors (Fig. 5f) and utilised neutrophils, as a control
to assess effects of mitochondrial inhibition on traditional
NADPH oxidase-driven respiratory burst. As expected, complex
I (CI) inhibition had no impact on neutrophil respiratory burst
(Fig. 5g). Conversely, pTRMØ respiratory burst was highly
dependent on respiratory-chain complexes I, II and III (Fig. 5h).
Inhibition of ATP synthase (linker of the respiratory-chain to
OXPHOS), had a less dramatic impact (Fig. 5h), suggesting the
respiratory-chain is decoupled during zymosan phagocytosis,
which is supported by the obeservation of increased proton leak
(Fig. 5b). Unlike neutrophils, pTRMØ have substantial basal-
OCR, suggesting inhibition of vital OXPHOS components may
affect phagocytosis itself. Indeed, reductions in pTRMØ
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(n= at least 3 separate wells per group) represent two independent experiments and were analysed by Student’s t-test. All error bars denote mean± SEM
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phagocytosis were observed after CI or complex III (CIII)
inhibition, but not CII (Fig. 5i). To control for this, electron
transport complex inhibitors were used after zymosan uptake.
The effect of these drugs on baseline OCR was compared to those
recorded 90 min post-zymosan (Fig. 5j). CI inhibition had similar
effects pre-and post-zymosan, indicating that CI function is
necessary both before and during respiratory burst. Remarkably,
CII inhibition did not substantially affect basal mitochondrial
OCR, but drastically reduced the zymosan-induced OCR,
demonstrating that CII engagement is enhanced during respira-
tory burst. Inhibition of CI or CIII had similar effects on basal-
OCR. However, CIII inhibition during respiratory burst had a
much greater impact, nearly eliminating both basal and zymosan-
induced mitochondrial OCR. Together, these data strongly
support a model wherein CI and CIII support basal pTRMØ
OCR with little input from CII; however, during respiratory burst,
CII engagement increases, supplying additional electrons to
enhance OCR via CIII. This could affect ATP production
(OXPHOS) or result in CIII-derived reactive oxygen species
(ROS)30–32. It should be noted that, despite minimal short-term
effects of CII inhibition on OCR (<1 h), long-term inhibition (5 h)
did substantially suppress OCR (Fig. 5k); showing that CII is
required for long-term basal metabolism, but it does not directly
contribute to measured basal-OCR.
The increased utilisation of CII and the requirement for
glutaminolysis are often linked. The product of glutaminolysis, α-
ketoglutarate, results in TCA-supplied succinate, and glutamate
can also pass through the GABA shunt to fuel CII (succinate
dehydrogenase)33. Indeed, we found that glutaminolysis enhance-
ment of zymosan-induced OCR is lost after CII inhibition
(Fig. 5i), demonstrating that glutamine facilitates increased
pTRMØ CII activity.
Together these data demonstrate that pTRMØ are pre-
programmed to exploit tissue-niche fuels to deliver a
mitochondrially-driven respiratory burst through enhanced
utilisation of CII.
PTRMØ metabolic changes are independent from TLR and
NO. Recently, Garaude et al.34 suggested that BMDM alter their
mitochondrial supercomplex structures to favour CII activity
after sensing bacterial RNA through Ticam1- and Myd88-
dependent pathways. In contrast, decoupling the mitochondrial
oxidative chain, part of the mitochondrial stress test, is sufﬁcient
for CII-dependent maximum pTRMØ mitochondrial capacity
(Fig. 6a) and this dependency was unchanged after zymosan
addition (Fig. 5c). Moreover, we recorded comparable levels of
CII function before and after zymosan in pTRMØ (Fig. 6b).
These data show, that unlike BMDM, which enhance their
maximal mitochondrial capacity after activation via super-
complex changes34, zymosan-stimulated pTRMØ do not.
Although, we considered it unlikely that zymosan contains
intact RNA, it does contain ligands for Toll receptors, which
could stimulate similar pathways in pTRMØ. Thus, we tested
whether increased CII-dependent OCR might be independent
from Toll-like pathways by comparing metabolic changes after
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Fig. 5 Peritoneal tissue-resident macrophages enhance mitochondrial function during respiratory burst through a glutaminolysis enhancement of complex-II. a
Peritoneal tissue-resident macrophage (pTRMØ) and neutrophil basal-OCR. Data show at least 10 wells per group and represents three observations. b
Changes in mitochondrial parameters after zymosan (50 μg/ml) to pTRMØ. Data (n= 6 separate wells per group) represent three experiments analysed by
paired two-way ANOVA (interaction p<0.0001) with Sidak’s post-tests. c The maximal mitochondrial capacity from b. d Graph showing the total oxygen
consumption of neutrophils after zymosan, ±VAS-2870 (10 μM). Data (9 wells per group from three experiments) were analysed by two-way ANOVA
(interaction p=0.8567), *** the signiﬁcant effect of VAS-2870 (p=0.0005). e Oxygen consumption of pTRMØ as in d. Data (6 wells per group from two
experiments) were analysed by two-way ANOVA (interaction p=0.138), * the signiﬁcant effect of VAS-2870 (p=0.0331). f A simpliﬁed diagram of the
electron transport chain (ETC). Inhibitors are shown in red. g The effect of rotenone (200 nM) on total oxygen consumption of neutrophils after zymosan. Data
show three wells per group and represents three experiments. h The total oxygen consumption of pTRMØ after addition zymosan in the presence of the ETC
inhibitors: oligomycin (1.26 μM), rotenone (200 nM), thenoyltriﬂuoroacetone (TTFA, 2mM), antimycin A (1 μM). Data show three wells per group, represents
two experiments and were analysed by one-way ANOVA (p<0.001) with Tukey’s post-tests vs control. i The effect of metabolic drugs f and 2-deoxyglucose
(2-DG,100mM) on the uptake of pHrodo zymosan(50 μg/ml,1 h). Data were analysed by one-way ANOVA (p<0.001) with Tukey’s post-tests vs control. j
Graph showing change in OCR after addition of indicated drugs f and atpenin A5 (1 μM). Post treatment (Post) is 90min after zymosan, pre-treatment occurs
before zymosan (Pre). Data show three wells per group, represents at least two experiments and were analysed by two-way ANOVA (interaction p<0.0001)
with Sidak’s post-tests. k The effect of a 5 h atpenin treatment on OCR in pTRMØ. l Graph showing total oxygen consumption of zymosan-induced pTRMØ
after atpenin A5 ±glutamine. Data (6 separate wells per group) is a pool of two experiments and was analysed by two-way ANOVA (Interaction p=0.0079)
with Sidak’s post-tests. All error bars denote mean± SEM, except c which shows the median, data in a, c, g, k were analysed by Student’s t-test
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zymosan in Tlr2−/−, MyD88−/− and Ticam1−/− pTRMØ.
Zymosan-induced pTRMØ metabolic changes were unaffected
in these mice (Fig. 6c, d), showing that CII enhancement can
occur independently of toll-like receptor/ bacterial RNA-sensing
in these cells. Nitric oxide (NO) synthase (NOS) also consumes
oxygen, produces free radicals, and has been shown to affect
mitochondrial function35. However, respiratory burst was not
perturbed in Nos2−/− pTRMØ (Fig. 6e). Taken together, these
data demonstrate that although BMDM may require TLR-
mediated RNA sensing for mitochondrial changes in response
to bacteria, pTRMØ are poised to engage enhanced CII-mediated
metabolism independently of TLR signalling.
PTRMØ metabolic changes require protein kinase C. Garaude
et al.34 reported that the metabolic switch to CII was entirely
dependent on NOX2 in BMDM, conversely, we found that NOX2
inhibition had relatively minor effects on pTRMØ zymosan-
induced oxygen consumption (Fig. 5e). However, pharmacolo-
gical inhibition does not always completely eliminate activity,
therefore we studied the burst in pTRMØ from mice lacking
nuclear cytosolic factor-1 (Ncf1−/−), a vital NOX2 component.
These cells showed no impairment in zymosan phagocytosis
(Fig. 7a). However, respiratory burst was reduced, which is
remarkable considering enhanced OCR was dependent on
mitochondrial function, and that inhibition had little effect
(Fig. 5e). Despite these reductions, we observed a similar pattern
of increased OCR in response to zymosan, albeit at lower mag-
nitude (Fig. 7b). This suggested some NOX2 activity is required
for ampliﬁcation of mitochondrial changes during respiratory
burst, but is not required for engagement of CII. Indeed,
enhanced oxygen consumption during the Ncf1−/− pTRMØ
respiratory burst was dependent on CII (Fig. 7c, d).
Enhancement of CII in zymosan-induced pTRMØ respiratory
burst is independent of TLR signalling, therefore we investigated
other mechanisms. protein kinase C (PKC) activation occurs
downstream of dectin-1/Syk signalling, which are activated by
zymosan in MØ36, 37. However, Dectin-1 is required for zymosan
recognition in phagocytes36, so it may be required for engulfment
as well as downstream signalling. To assess the role of PKC
directly, we used phorbol–myristate–acetate (PMA). PMA does
not interfere with dectin-1/Syk-mediated phagocytosis, but
directly activates PKC. PMA treatment results in a short burst
in OCR, the amplitude of which was dependent on NOX2 activity
(Fig. 7b). However, PMA also enhanced mitochondrial function in
Ncf1−/− pTRMØ (Fig. 7b), which was dependent on mitochondrial
electron transport complexes (Fig. 7e), and elevated CII activity
(Fig. 7f). We conﬁrmed the requirement for PKC, through
equivalent inhibition of zymosan or PMA-induced respiratory
burst with a PKC inhibitor (Fig. 7f). The lower magnitude
respiratory bursts seen with the addition of other ligands was, in
the majority of cases, PKC-dependent (Supplementary Fig. 6c).
Collectively, these data show that PKC activation can increase
mitochondrial engagement of CII in pTRMØ independently of
NOX2, however residual NOX2 activity may facilitate enhance-
ment of these mitochondrial changes during phagocytosis.
The pTRMØ metabolic switch supports the production of
ROS. CII-dependent OCR increases during respiratory burst
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could have consequences for cell functionality via free radical
production, ATP synthesis and/or NADPH recycling. ATP is
required for lysosome acidiﬁcation38 and organelle movement,
whereas NADPH is utilised for NOX2 activity and maintains
cellular redox states. Therefore, we assessed ATP and NADPH
after fuel deprivation in pTRMØ, conditions demonstrated to
alter respiratory burst after zymosan. Although ATP was drasti-
cally reduced after treatment with zymosan, absence of glucose or
glutamine did not greatly affect ATP levels (Fig. 8a). NADPH was
reduced after zymosan regardless of the availability of glucose or
glutamine (Fig. 8a). This negligible effect of fuels on ATP and
NADPH levels is distinct from patterns we observed in OCR
(Fig. 3d), and contrasted with neutrophils which exhibited an
absolute requirement for glucose in the maintenance of
ATP levels, NADPH levels (Fig. 8b) and zymosan-induced OCR
(Fig. 4c, d). The insigniﬁcant effects of fuel starvation on ATP and
NADPH levels in pTRMØ demonstrates that these cells are
metabolically plastic. Indeed, inhibition of metabolic pathways
revealed that pTRMØ were not dependent on any singular
pathway for maintenance of NADPH. However, we found
substantial dependence on glycolysis rather that OXPHOS for
ATP production (Fig. 8c). Taken together, these data support the
conclusion that pTRMØ have robust metabolic plasticity, which
compensates for the lack of fuels, whereas neutrophils are
dependent on glucose.
An alternative mechanism for the involvement of mitochondria
in respiratory burst is direct contribution to respiratory burst via
mitochondrial superoxide and hydrogen peroxide. Zymosan non-
speciﬁcally binds many mitochondrial targeted dyes (Fig. 9c, d).
Therefore, we used PMA to assess mitochondrial capacity for
producing superoxide. To limit NOX-derived ROS contamina-
tion, we used Ncf1−/− pTRMØ. PMA treatment increased
mitochondrial superoxide in Ncf1−/− pTRMØ (Fig. 8d). Using a
hydrogen peroxide probe, we tested whether localised superoxide
production in the mitochondria is indicative of general produc-
tion of free radicals. Addition of zymosan to pTRMØ resulted in a
hydrogen peroxide burst, which correlated with the respiratory
burst measured by OCR. The hydrogen peroxide burst was
sensitive to glutamine-deprivation or electron transport inhibi-
tion (Fig. 8e). These data demonstrate that complex-II dependent
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OCR correlates with ROS production, supporting that
glutaminolysis supplies the electron transport chain to fuel
pTRMØ mitochondrial ROS production during the response to
zymosan.
PTRMØ CII metabolism ﬁne-tunes cytokine production. MØ-
derived cytokines are secreted in response to microbes or tissue
damage and control inﬂammation1. TRMØ produce inﬂamma-
tory mediators in response to S. cerevisiae, the microorganism
from which zymosan is derived. Using two inhibitors, we mea-
sured speciﬁc effects of CII inhibition on S. cerevisiae-induced
pTRMØ cytokine production. Interestingly, CII inhibition con-
sistently reduced production of interleukin (IL)-10 and tumour
necrosis factor (TNF), whereas IL-1β (mRNA and mature pro-
tein) and the neutrophil chemoattractant CXCL-1 (KC) were
unaffected or inconsistently changed (Fig. 9a, b). Surprisingly, a
different CII inhibitor, dimethylmalonate, had no effect on Il1b
mRNA, but blocked ATP-induced secretion of IL-1β (Fig. 9a, b).
Collectively, this shows that CII activity is required to ﬁne-tune
macrophage functional responses, which predictably will impact
inﬂammatory resolution.
PTRMØ mitochondria are recruited to the cytotoxic phago-
some. We next investigated whether pTRMØ mitochondria
associate with the phagolysosome, which would allow mito-
chondria to directly affect phagolysosome content, as has been
reported in BMDM and monocytes39, 40. The pTRMØ mito-
chondrial network is vast and tubular (Fig. 9c; Supplementary
Movies 3–4) and ingestion of zymosan did not alter mitochon-
drial size signiﬁcantly (Fig. 9f). However, after phagocytosis,
zymosan is often situated near mitochondrial networks (Fig. 9c),
which may represent mitochondrial recruitment to the phagoly-
sosome39. Indeed, in some cases, as reported40, three-dimensional
cupping of phagolysosomes with mitochondria was observed
(Fig. 9d). Linear regression analysis conﬁrmed enrichment of
mitochondria toward the phagolysosome (Fig. 9e, R2 = 0.7162,
non-zero p< 0.0001) making them well-situated to control the
outcome of pTRMØ phagolysosome function.
We examined whether mitochondrial function was important for
the killing of phagolysosome contents. Unexpectedly, addition of
the CII inhibitor did not signiﬁcantly reduce the killing of S.
cerevisiae by pTRMØ (Fig. 9g), as has been reported in the BMDM
killing of bacteria34. This could be attributed to residual
mitochondrial function after CII inhibition, which is capable
of producing sufﬁcient ROS to kill S. cerevisiae, while we ﬁnd
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that CIII is required for most pTRMØ ROS. Thus, in contrast to
CII, CIII inhibition had a marked impact, even when added post S.
cerevisiae to permit unadulterated uptake (Fig. 9h). This strongly
suggested that reduced free radical production in the absence of CII
activity is sufﬁcient for antimicrobial function, whereas CIII
inhibition may reduce mitochondrial function below the threshold
required for effective antimicrobial activity. Collectively, these data
suggest that pTRMØ mitochondria move toward phagolysosomes
where mitochondrial function contributes to the killing of ingested
microbes.
Discussion
Relatively little is known about TRMØ metabolism. Past research
revealed that human leucocyte phagocytosis correlates with glu-
tamine availability in the blood41, and that glutamine was
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Fig. 9 The mitochondrial electron transport chain is required for antimicrobial function in peritoneal tissue-resident macrophages. a Quantiﬁcation of
cytokines from peritoneal tissue-resident macrophage (pTRMØ) supernatant 24 h after Saccharomyces cerevisiae (S. cerevisiae) (50 μg/ml)
±dimethylmalonate (DMM,10mM) or ±atpenin A5 (1 μM). The far-right panel shows IL-1β after 1 h post-stimulation with adenosine triphosphate (ATP, 3
mM), 23 h after S. cerevisiae. Data (n= 4 separate wells per group) represent two independent experiments. For TNF, IL-10 and KC, data were analysed by
one-way ANOVA with Dunnett’s post-tests; for IL-1β, data were analysed by two-way ANOVA with Sidak’s post-tests vs vehicle control or vs no ATP as
indicated (interaction p< 0.0001, ATP p< 0.0001, complex-II p< 0.0001). Error bars=mean± SEM. b Relative expression of Il1b RNA from samples in a.
c Representative photographs of pTRMØ. In c, d, zymosan-AlexaFluor488 (5 μg/ml) are green, mitochondria labelled with Mitotracker Red CMX-Ros (25
nM) are red, whereas the nuclei are labelled blue with 6-diamidino-2-Phenylindole (DAPI,125 ng/ml). The yellow box denotes mitochondria surrounding
zymosan. Zymosan cores can be seen with non-speciﬁc Mitotracker Red ﬂuorescence. d A characteristic z-stack showing mitochondria surrounding the
phagolysosome. The yellow numbers denote distance from coverslip. e Quantiﬁcation of the number of Mitotracker Red positive pixels expressed as
percentage of total (termed mitochondrial localisation %) at different radial distances from zymosan. Data shown are 53 zymosan particles from ﬁve
images. Data were analysed by a one-way ANOVA (p< 0.0001) with a linear regression post-test shown. f Box and whisker plots showing quantiﬁcation of
size for >800 mitochondrial units per group taken from ﬁve images of pTRMØ in the presence or absence of zymosan-AlexaFluor488. g Representative
pictures (left) of microbial plates with S. cerevisiae colonies. Data shown are from S.cerevisiae cultured± pTRMØ with atpenin A5 (1 μM) or control for 4½ h.
The graph on the right shows quantiﬁcation of the average microbial killing. Data are from three experiments (n= 13 per group) and were analysed by two-
way ANOVA (interaction + experimental repeat p= 0.26, atpenin A5 p= 0.10). h Representative pictures (left) and quantiﬁcation of data (right) as in e,
but with antimycin A (1 μM) or control. Data are from four experiments (n= 18 per group) and were analysed by two-way ANOVA (interaction +
experimental repeat p= 0.10, antimycin A p< 0.0001). Whiskers e–h show 10–90% of the range. White scale bars are 10 μm
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-02092-0
10 NATURE COMMUNICATIONS |8:  2074 |DOI: 10.1038/s41467-017-02092-0 |www.nature.com/naturecommunications
important for interleukin production42, 43. Newsholme, Gordon
and colleagues demonstrated that pTRMØ have an innate ability
to use glutamine, but do not fully utilise this capacity during
homoeostasis24, 44. Therefore, we hypothesised that pTRMØ
glutamine metabolism could be maximised during stress, and
might be limited by glutamine availability in the tissue
environment.
In vitro-derived BMDM have been routinely used to study MØ
functions, however TRMØ have different origins and are at the
front-line of tissue defence. We hypothesised that examining
these cells in context with their niche environment might reveal
unique characteristics and/or mechanisms2. On the basis of this
approach, we propose a model (Fig. 10) where peritoneal-
enriched fuels support metabolic repurposing of pTRMØ during
stress. PTRMØ have considerable mitochondrial capacity fuelled
by peritoneal glutamate/ glutamine, which supports CII-
dependent repurposing of mitochondrial metabolism after pha-
gocytosis and during stress. This metabolic switch is distinctive to
a mechanism described in in vitro-derived BMDM34; can be
initiated through PKC activation, and is required for pTRMØ
ROS. Furthermore, we demonstrate that pTRMØ mitochondrial
function is required for nominal cytokine expression and
microbial killing.
PTRMØ have increased TCA metabolites, larger mitochondrial
networks and a greater OXPHOS capacity compared to in vitro-
derived BMDM. RNA-seq analysis did not uncover a causal basis
for these differences, though it revealed opposite metabolic iso-
form expression patterns between these populations. Differential
utilisation of metabolic transcriptional programmes may underlie
distinct mitochondrial phenotypes and function, although more
study is needed to dissect these mechanisms. Alternatively,
mitochondrial differences we describe may be the result of cell-
speciﬁc reactions to non-physiological oxygen and metabolic fuels
in vitro or reﬂect different rates of proliferation. Mitochondrial
network volumes are known to ﬂux as the cell-cycle progresses45.
As the proliferation rate of pTRMØ is very low3 compared to that
of BMDM, we cannot rule out that our ﬁndings are a reﬂection of
“resting” vs “proliferative” mitochondria. Despite these caveats,
when taken together with our metabolic proﬁling, these data
show that in vitro-derived MØ are phenotypically and metabo-
lically distinct to pTRMØ, suggesting their specialised metabolic
programming is vital for cell-speciﬁc functions in unique envir-
onments in situ.
We found the peritoneal metabolome to be distinct from
serum, containing elevated amino acids, especially glutamate.
Glutamate supplements glutamine’s ability to support pTRMØ
mitochondrial function, demonstrating that glutamate produc-
tion is limiting for pTRMØ metabolism in situ. The peritoneal
metabolome also supports the proposed role of Aspa for pTRMØ
survival12, by demonstrating that, compared to serum, the peri-
toneum is enriched with the Aspa substrate NAA. Thus, we now
know of two examples where the niche environment provides
factors required to speciﬁcally control pTRMØ phenotype and
function. Interestingly, glutamate is also a neurotransmitter. The
source of peritoneal glutamate and NAA is unknown, although
they may be released from neurons and/or the gut micobiome46.
Regardless, substantial presence of glutamate and NAA in the
peritoneum is consistent with the known interplay of para-
sympathetic nerve function, gut physiology and inﬂammation.
We ﬁnd that zymosan-induced pTRMØ respiratory burst is
glucose-dependent, fatty acid-independent and required gluta-
minolysis, a metabolic pathway supported by peritoneal-enriched
glutamate. Surprisingly, zymosan-induced increases in OCR were
attributable to increases in mitochondrial function. This explains
the glutaminolysis requirement and it demonstrates that pTRMØ
respiratory burst is fundamentally different from that of neu-
trophils, where increases in OCR can be entirely attributed to
NOX activity, which requires glucose-fuelled maintenance of
NADPH25. In pTRMØ, respiratory burst was not dependent on
opsonisation and TLR2 was not required, but other receptors
such as dectin-1 may be important36, 47, as both PMA and
zymosan initiated mitochondrial-dependent respiratory bursts
that were PKC-dependent. Interestingly, pTRMØ respiratory
burst was accompanied by a burst in ECAR, suggesting that
enhanced glycolysis may also be important; likely to supply
additional ATP required for cell activation, which is consistent
with the glycolytic-dependency of ATP production (Fig. 8c).
The metabolic reprograming toward increased CII metabolism
in pTRMØ we describe was not dependent on live bacterial
sensing, as in BMDM34. Rather our data suggest that pTRMØ are
metabolically poised to switch toward increased CII activity
in situ. A priming event, such as sensing of the microbiome48,
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may be required for this in vivo. Such signalling is absent in
cultured BMDM, but could be triggered via TLR-sensing of live
bacteria in vitro34. We demonstrate that pTRMØ enhancement of
complex-II activity does not require the NOX2 component NCF-
1, despite a reduced amplitude in the absence of NCF-1. Notably,
we ﬁnd distinct differences between biochemical suppression of
NOX2 and genetic ablation; the former having little effect,
whereas the latter effectively reduces burst. This seemingly
paradoxical ﬁnding suggests that other cellular oxidases could
speciﬁcally allow for the shift in mitochondrial function in the
absence of NCF-1, whereas NOX2 may amplify burst via positive
feedback, or be needed for a priming event in vivo that is not
effectively inhibited pharmacologically. Such a model is sup-
ported by examples of NOX2 activating other oxidases and
facilitating the generation of mitochondrial ROS30, 49. It is likely
that glucose is required for PPP-fuelling of NOX2, as in the
absence of glucose, but presence of glutamine, there is a reduced
zymosan-induced OCR enhancement. Therefore, we propose that
pTRMØ use glucose to activate NOX2 and maintain ATP,
however the increased oxygen consumption is derived from
NOX2-ampliﬁcation of mitochondrial function and fuelling from
glutamine, rather than NOX2 activity itself. Incidentally, we
detected glutamine- and PKC-dependent increases in OCR from
other ligands. However, these were of much lower magnitude
than zymosan- or PMA-induced OCR. This could be attributed to
a lack of NOX engagement, but could also indicate lower PKC
activation or reduced uptake/binding of ligands.
Respiratory burst was not detected in BMDM, despite similar
rates of zymosan uptake (Supplementary Fig. 7), perhaps due to
long-term suppressive effects of exogenous M-CSF on NOX2
components in BMDM50 or other downstream signalling
mechanisms. Accordingly, cultured human monocytes also
undergo a glutaminolysis-dependent respiratory burst, but only
after interferon gamma pre-treatment to maintain NOX expres-
sion in vitro51. Thus, the respiratory burst enhancement through
glutaminolysis we describe is not organism restricted, but may
require NOX for optimum effectiveness.
Respiratory burst H2O2 production in pTRMØ may be sup-
ported by mitochondrial superoxide via CIII30, 32, or the NOX-
fuel NADPH via mitochondrial shuttles52, 53. Yet, we ﬁnd that
NADPH levels did not correlate with OCR changes, suggesting
that mitochondrial ROS is responsible for glutaminolysis-
enhanced H2O2. The near total sensitivity of zymosan-induced
pTRMØ ROS to antimycin A is consistent with electron leak
from CIII, rather than reported reverse electron transport from
CII to CI54. We ﬁnd that pTRMØ do not require CII to maintain
their basal-OCR short-term, but increase their dependence on CII
after phagocytosis. In fact, OXPHOS through CI does not require
the full TCA cycle or CII, but purely requires NADH that can be
supplied by mitochondrial shuttles55. Inhibition of OCR after
long-term CII inhibition is likely attributable to a build-up of
TCA metabolites, which could ultimately inhibit NADH avail-
ability and subsequently affect CI activity.
In addition to effects on respiratory burst, the switch toward
increased CII activity in pTRMØ was also required for optimal
cytokine secretion. Interestingly, ATP-induced IL-1β secretion
was reduced after treatment with dimethylmalonate but not by
atpenin A5 (CII inhibitors), whereas TNF and IL-10 were sup-
pressed by both. Unlike atpenin A5, dimethylmalonate is a
competitive inhibitor, which could affect succinate transporters
and succinylation reactions. It is also known to inhibit citrate
synthase56 and all these processes have been implicated in reg-
ulation of IL-1β making its effects difﬁcult to interpret54. In
addition, these inhibitors are likely to alter ROS, a signal known
to activate the inﬂammasome and drive cytokine expression54, 57.
NO production is another possible explanation for effects on
inﬂammatory pathways. We have previously shown that LPS
drives NO production, which directly suppresses OXPHOS in
BMDM35, reportedly by the suppression of mitochondrial com-
plexes58. Therefore, inhibition of CII in BMDM could affect
many factors, including NO production or its effect. However,
pTRMØ stimulated with zymosan or S. cerevisiae do not produce
appreciable NO (Supplementary Fig. 8), which is perhaps related
to high arginase expression11 known to inhibit NOS59. Thus,
unlike BMDM, pTRMØ metabolic control in situ is likely to be
largely independent of NO, which will affect the outcome of cell
activation and inﬂammation.
Consistent with a role in respiratory burst, we found that
pTRMØ recruit mitochondria toward phagolysosomes as has
been shown in BMDM39, 40, 60, the latter dependent on TLR
signalling. Interestingly, mitochondrial recruitment to zymosan-
phagolysosomes was maintained in Tlr2−/− pTRMØ (Supple-
mentary Fig. 9), conﬁrming their predisposition for response.
Complete inhibition of mitochondrial function and subsequent
ROS production using a CIII inhibitor impaired pTRMØ killing
of microbes. It has been suggested that ROS in neutrophils pri-
marily activates granule enzymes rather than directly killing
microbes61. Given that ROS production is lower in MØ than
neutrophils, it is unlikely that ROS production from MØ directly
kills microbes, but rather, as with neutrophils, acts as a secondary
messenger. Regardless, we ﬁnd that peritoneal metabolites, which
fuel pTRMØ mitochondrial function are important in the
response to and the killing of microbes.
In summary, for the ﬁrst time, we examine TRMØ metabolic
requirements with consideration of the corresponding tissue-
niche environment. We demonstrate that pTRMØ are uniquely
poised to utilise tissue-niche fuels to defend against microbial
challenge. Further understanding of the metabolic requirements
of effector cells in their unique tissue-niches will have meaningful
impacts on our approach to treating disease in a tissue-dependent
manner.
Methods
Reagents. All reagents were from Sigma unless otherwise stated. Speciﬁc kits and
linked reagents are described below. Non-canonical reagents are listed.
Rotenone, dehydroepiandrosterone (DHEA), thenoyltriﬂuoroacetone (TTFA),
antimycin A, 2-deoxyglucose (2-DG), oligomycin, glutamate (pH 7.4 with NaOH),
zymosan particles from Saccharomyces cerevisiae (including pHrodo, Thermo-
Fisher), Yeast from Saccharomyces cerevisiae, LPS (lipopolysaccharide), luminol,
DTAC (Dodecyltrimethylammonium chloride), Accutase, diazo-oxo-norleucine
(DON), bis-phenylacetamido-thiadiazolyl-ethyl sulphide (BPTES), atpenin A5
(Cayman chemicals), dimethylmalonate, UK-5099, etomoxir,
phorbol–myristate–acetate (PMA), mitotracker red CMX-Ros (Thermo-Fisher),
all-trans retinoic acid, M-CSF (Peprotech), VAS-2870, Sotrastaurin (Cayman
chemicals), N-Formylmethionyl-leucyl-phenylalanine (fMLF), Pam3CSK4
(Invivogen), uric acid crystals, R848 (Invivogen), 4′,6-Diamidino-2-Phenylindole
(DAPI, Thermo-Fisher), Hoescht 33342 (Thermo-Fisher), 2-mercaptoethanol.
Mice. Mice were on the C57BL/6 background and maintained in the Frederick
National Laboratory Core Breeding Speciﬁc Pathogen Free Facility. NOX2 deﬁcient
NCF-1−/− (Ncf1−/−) mice62 were a kind gift from Dr. Steven Holland (National
Institute of Allergies and Infectious Diseases, Bethesda, USA). Nos2−/− mice63 were
a generous gift from Dr. Victor Laubach (University of Virginia). Myd88−/− mice64
were a gift from Dr. Giorgio Trinchieri, National Cancer Institute (NCI), Bethesda.
Ticam1−/− mice were backcrossed onto the C57BL/6 background in our core
facility65. Animal care was provided in accordance with the procedures in, “A
Guide for the Care and Use of Laboratory Animals”. Ethical approval for the
animal experiments detailed in this manuscript was received from the Institutional
Animal Care and Use Committee (Permit Number: 000386) at the National Cancer
Institute-Frederick. Experiments were carried out on a mixture of male and female
mice between 6 and 16 weeks of age.
Primary cell preparation and puriﬁcation. Bone marrow leucocytes66 and peri-
toneal cells11 were isolated as previously described. Brieﬂy, for peritoneal cells, the
peritoneum of a mouse was lavaged with 5–10 ml phosphate buffered saline (PBS)
using a 21-G needle. For bone marrow leucocytes, bone marrow was ﬂushed out of
trimmed leg bones using PBS and a 25-G needle. Red blood cells were lysed before
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cell culture. BMDM were differentiated from these cells and maintained using
20 ng/μl recombinant mouse M-CSF as previously described66.
For magnetic puriﬁcation of primary cell populations: Cells were blocked with
4 μg/ml α-FcγIII (2.4G2, in house) in wash buffer PBS with 5 mM
ethylenediaminetetraacetic acid (EDTA), 0.5% bovine serum albumin (BSA)) for 5
min on ice, before addition of 20 μg/ml α-Ly-6G-Biotin (1A8, Biolegend) to label
neutrophils or 20 μg/ml α-F4/80-Biotin (BM8, Biolegend) to label pTRMØ for 30
min on ice. Cells were then magnetically sorted with streptavidin micro-beads and
LS columns as per manufactures instructions (Miltenyi Biotec), with an additional
wash of 3 ml complete media (Dulbecco’s minimal essential media (DMEM) with
no pyruvate, 10 % fetal calf serum (FCS), 0.2 units/ml penicillin, 100 µg/ml
streptomycin, 2 mM L-glutamine, 25 mM glucose) (Thermo-Fisher) for pTRMØ, or
Seahorse media (Seahorse Bioscience) for neutrophils to remove EDTA, before
elution of the positive selection in complete media or Seahorse media. Purities were
typically 90–95% for neutrophils and 85–90% purity for pTRMØ, with the major
peritoneal contaminant primarily being F4/80+ eosinophils.
Human monocytes were obtained by gently adding 35 ml blood to 15 ml
Histopaque (Ficoll) in a 50 ml centrifuge tube. The tube was centrifuged for 30 min
at 600×g at room temperature. The peripheral blood mononuclear cell (PBMC)
layer was removed to a centrifuge tube and re-suspended to 50 ml with cold PBS
(+2 mM EDTA). This was again centrifuged for 5 min at 600×g and the
supernatant removed, the cells were washed two more times with PBS (+2 mM
EDTA). The Percol kit (GE Healthcare, 17-0891-01) was used to purify monocytes.
Brieﬂy, PBMCs were re-suspended in 5 ml of solution A and this solution gently
layered into a 15 ml centrifuge tube containing a 54:47 mixture of solution A to
solution B. The tubes were centrifuged for 30 min at 1000×g, and the monocyte
band removed, re-suspended in complete media and counted. Human blood was
obtained from healthy volunteers, who were recruited through the National Cancer
Institute-Frederick Research Donor Program and provided written informed
consent. All users of human materials were approved and appropriately trained.
Extracellular ﬂux analysis. For neutrophil adherence, wells of an extracellular ﬂux
(XF) tissue culture plate were treated with Cell-Tak solution as per manufacturer’s
instructions (Corning), however this was found to be unnecessary for adherence.
Magnetically sorted pTRMØ were seeded at 0.5–1.0 × 106 (24-well) or 0.25 × 106
cells per well (96-well) in complete media (+0.5 μM retinoic acid, + 20 ng/ml M-
CSF) and incubated for 1.5–2 h. The media was removed and replaced with Sea-
horse assay media with 2 mM glutamine and 25 mM Glucose (+0.5 μM retinoic
acid, +20 ng/ml M-CSF) unless stated. Magnetically sorted neutrophils (1.0 × 106
cells per well, 24-well) in Seahorse assay media were also added to the Seahorse
plate. The neutrophils were centrifuged to the bottom of the well at the lowest
acceleration to 45×g followed by natural deceleration. Fully differentiated BMDM
were removed from plates with a 10 min incubation of accutase solution (37 °C)
and ﬁrm washing. Cells were centrifuged for 5 min at 350×g, the supernatant
removed and the cells re-suspended in Seahorse media containing 20 ng/ml M-
CSF, before plating for seahorse analysis: 100,000 cells for 96-well, 400,000 cells for
24-well. Human monocytes (above) were cultured for 48 h at 2-million cells/ml in
the presence of recombinant human M-CSF (50 ng/ml) and interferon-γ (10 ng/
ml). Monocytes were removed from plates like BMDM above, with the exceptions,
that recombinant human M-CSF (50 ng/ml) and interferon-γ (10 ng/ml) were
added to the Seahorse media and cells were plated in the same concentrations as
pTRMØ. The plates containing cells were incubated for 1 h at 37 °C with no CO2.
XF analysis was performed at 37 °C with no CO2 using the XF-24 or XF-96 ana-
lyzer (Seahorse Bioscience) as per manufacturer’s instructions. Port additions and
times were used as indicated in the ﬁgures. Lavaged media was also used to replace
media on pTRMØ, brieﬂy, 0.5 ml of Seahorse XF base media (no glucose or glu-
tamine) was used to peritoneal lavage mice, with extra mixing. This lavage media
was centrifuged at 500×g for 10 min, to remove cells, the supernatant removed and
added to an Amicon 3 kD centrifugal ﬁlter (Millipore). This was centrifuged at
3000×g for 60 min, to remove large proteins.
For apoptotic thymocytes: Thymuses were extracted and mechanically
dissociated in complete RPMI media. Cells were re-suspended and counted in
complete media. Thymocytes were seeded in 6-well plates (10 × 106 per well) with
dexamethasone (1 μM) for 3 h. Cell were extracted from plates and washed three
times in seahorse base media before re-counting and loading into injection ports
(500,000 cell per well). Cells were additionally labelled using the PE Annexin V
Apoptosis Detection kit (Becton Dickinson) as per manufacturer’s instructions. On
average apoptosis was recorded as 20–40% exposure of phosphatidylserine with
<10% dead cells.
Flow cytometry. For zymosan uptake: pHrodo zymosan particles (50 μg/ml) was
added to cells for 1 h or mitoSOX Red (2.5 μM) was added to cells for 20 min. Cells
were washed with PBS and detached from culture plates using Accutase treatment
at 37 °C for 15 min, before thorough pipetting. Cells were transferred to ﬂow
cytometry tubes and analysed by a BD LSRII or BD Fortessa ﬂow cytometer for
ﬂuorescent analysis. Doublets and debris were gates out before quantiﬁcation of
median ﬂuorescent intensities with FlowJo (FlowJo, LLC).
For apoptosis detection: Cells were transferred to ﬂow cytometry tubes and
analysed by a BD LSRII ﬂow cytometer. Doublets were gates out before evaluation
of % Annexin V+ 7AAD− (apoptotic) and % Annexin V+ 7AAD+ (dead) with
FlowJo (FlowJo, LLC) (Supplementary Fig. 10).
For purity checks: α-F4/80-Paciﬁc blue/ Alexa Fluor 647 (BM8, Biolegend) or α-
CD11b allophycocyanin-Cy7 (M1/70, Becton Dickinson) were used for pTRMØ,
and α-Ly-6G (1A8, Biolegend) or CD11b allophycocyanin-Cy7 was used for bone
marrow neutrophils (Supplementary Fig. 10).
Real-time polymerase chain reaction and RNA sequencing. For real-time
polymerase chain reaction: Atpenin A5 or dimethylmalonate were added 15 min
before 50 μg/ml serum-opsonized (15-min serum opsonization at 37 °C) S. cere-
visiae to 600,000 pTRMØ in wells of a 48-well plate (ﬁnal volume 250 μl). The plate
was incubated for 24 h before RNA was extracted using the High-Pure RNA iso-
lation kit (Roche, 11828665001), as per manufacturer’s instructions (with the
addition that 2-mercaptoethanol (1% v/v) was added to the lysis buffer). The High-
Capacity cDNA Reverse Transcription kit (Thermo-Fisher, 4368813) was used as
per manufacturer’s guidelines to generate cDNA from the RNA. Real-time PCR
was performed on an Applied Biosystems 7300 using Eagle Taq (Roche) reagent
and TaqMan gene expression probes: Hprt (Mm01545399_m1), IL-1b
(Mm00434228_m1) (Thermo-Fisher). Values are expressed as relative expression
using the ΔΔCt method: IL-1b cycle threshold number (Ct) minus Hprt Ct =ΔCt,
minus control sample ΔCt =ΔΔCt, relative expression considering the doubling
per cycle of PCR = 2−ΔΔCt.
For RNA-sequencing: RNA was taken from 1×106 naïve BMDM and pTRMØ
using the method above. RNA quality was assessed using Agilent BioAnalyzer
Nano chips and the RNA Integrity Number (RIN) algorithm. The RIN number was
8.3, 10, 10 and 10 for two pTRMØ and two BMDM samples respectively. RNA-Seq
libraries were constructed from 1 µg of RNA using the Illumina TruSeq Stranded
mRNA library preparation kit (Illumina, CA). Sequencing was done on Illumina
HiSeq 2500 sequencers, with two lanes of paired-end 125 bp reads generated per
sample. Raw ﬁles were aligned to mouse genome (mm10) using STAR (v. 2.3.0)67.
Normalisation was performed using trimmed mean of end values (TMM)68 after
ﬁltering out the genes that have ﬁve raw counts or less and were not shared by at
least one sample. The Limma-Voom69 paired test was used to obtain fold values.
Luminescence assays. Magnetically sorted pTRMØ were seeded at 0.2–0.4 × 106
cells per well of a 96-well luminescence plate in complete media and incubated for
2 h at 37 °C. The media was replaced with minimal media (DMEM with no pyr-
uvate, no phenol red, no glucose, no glutamine, 0.2 units/ml penicillin, 100 µg/ml
streptomycin), or Seahorse media (no glutamax, no glucose, no glutamine). Neu-
trophils were then added to separate wells on the plate and cells were supplemented
with ±glucose (25 mM) or ±L-glutamine (2 mM), or additional treatments as
indicated (including 400 µM luminol). The plate was incubated at 37 °C for 30 min,
after which ±zymosan (50 μg/ml) was added. For luminol measurements, the plate
was placed in a 96-well luminescence plate reader and luminescence readings were
measured every 6 min for 6 h. Otherwise, cells were lysed in passive lysis buffer
(Promega) or 0.1 M NaOH with 0.5% DTAC for ATP or NADPH determination,
respectively. Relative ATP was determined using the ATP assay kit (Abcam/
Thermo-Fisher) and NADPH/NADP ratios determined using the NADPH-Glo
assay kit (Promega) as per manufacturer’s instructions.
Primary metabolite analysis. Magnetically sorted pTRMØ or gently scraped
cultured BMDM (5.0–7.5 × 106) were pelleted and snap-frozen in liquid nitrogen.
A trypan blue dilution assay was used to determine the average ﬂuid quantity in the
peritoneum (Supplementary Fig. 11). This was determined to be ≈100 μl. Mice
were lavaged thoroughly with 300 μl of PBS to give a ≈4 × diluted lavage sample.
Blood collected in serum tubes and lavage samples were centrifuged at 1200×g for
15 min to remove cellular components. Serum was also diluted in PBS to give 4 ×
diluted serum samples. Samples were further processed and analysed at the West
Coast Metabolomic Center (University of California, Davis). Brieﬂy, samples were
re-suspended with 1 ml of extraction buffer (37.5% degassed acetonitrile, 37.5%
isopropanol and 20% water) at –20 °C, centrifuged and decanted to complete
dryness. Membrane lipids and triglycerides were removed with a wash in 50%
acetonitrile in water. The extract was aliquoted into two equal portions and the
supernatant dried again. Internal standards C08-C30 fatty acid methyl esters were
added and the sample derivatized by methoxyamine hydrochloride in pyridine and
subsequently by N-methyl-N-trimethylsilyltriﬂuoroacetamide for trimethylsilyla-
tion of acidic protons. Gas chromatography-time-of-ﬂight analysis was performed
by the Agilent GC6890/LECO Pegasus III mass spectrometer. Samples were
additionally normalised using the sum of peak heights for all identiﬁed metabolites.
Cytokine production and Saccharomyces cerevisiae killing. For cytokine analy-
sis: Atpenin A5 or dimethylmalonate were added 15 min before 50 μg/ml serum-
opsonized (15-min serum opsonization at 37 °C) Saccharomyces cerevisiae (S.
cerevisiae) to 600,000 pTRMØ in wells of a 48-well plate. The plate was incubated
for 24 h before supernatant removal. The BD cytometric bead array kit (558267)
was used to quantify cytokines in supernatant, and was used as per manufacturer’s
instructions. For killing quantiﬁcation: S. cerevisiae was added to pre-cultured
pTRMØ (described above) or empty wells in a 1:2 ratio. Antimycin A was added
was added 30 min after S. cerevisiae to avoid known defects in uptake. S. cerevisiae
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with or without pTRMØ were mixed with Triton-X100 (1% ﬁnal) by pipetting and
incubated for 5 min. Dilutions in water (1:10, 1:50, 1:200 ﬁnal) were plated (25 μl)
onto YPD-agar 9 cm bacterial plates using L-shaped spreaders. Plates were incu-
bated at 30 °C for 48 h before counting of colony numbers.
Confocal microscopy. For Fig. 9: pTRMØ were pre-cultured in complete media
(750,000 per 35 mm dish, + 0.5 μM retinoic acid, + 20 ng/ml M-CSF) for 18 h on
glass-bottom culture dishes (MatTek, #0). pHrodo zymosan particles (50 μg/ml)
were added to cells for 1 h and/or Mitotracker Red CMX-Ros (25 nM) was added to
cells for 20 min. Cells were washed twice with PBS and ﬁxed with 4% paraf-
ormaldehyde for 20 min at room temperature. Cells were washed with PBS and
6-Diamidino-2-Phenylindole (DAPI, 125 ng/ml) added. A Zeiss UV-510 confocal
microscope and 63x oil immersion objective lens was used to capture images using
differential interference contrast, 405, 488 and 561 nm laser paths (pinhole size = 1
airy unit).
For supplemental Figs. 4 and 7: pTRMØ (300,000 per 24-well, +0.5 μM retinoic
acid, +20 ng/ml M-CSF) or BMDM (150,000 per 24-well, +20 ng/ml M-CSF) were
seeded for 18 h on glass-bottom culture dishes (CellVis, #1.5). pHrodo zymosan
particles (50 μg/ml) were added to cells for 1 h and/or Mitotracker Red CMX-Ros
(25 nM) was added to cells for 20 min. Cells were washed twice with PBS and ﬁxed
with 4% paraformaldehyde for 20 min at room temperature. Cells were washed
with PBS and Hoescht 33342 (1 μg/ml) added before further washing. A Leica TCS
SP8 confocal microscope with Yokogawa CSUW1 spinning disk and a ×100 oil
immersion objective lens was used to capture images using 405, 488 and 561 nm
laser paths.
Images were analysed using Fiji (ImageJ)70. For quantiﬁcation of mitochondrial
proximity to the phagolysosome: Mitotracker positive pixels were quantiﬁed at
different radial distances from ﬂuorescent zymosan particles (up to 5 μm) and data
were expressed as percentage of total mitochondrial localisation. The 3D objects
counter71 was used to calculate approximate mitochondrial volumes, which is
based on 65 nm2 per pixel and a 100 nm z-step size, to give voxels of 6500 nm3. 3D
models visually ﬁt the data well (Supplementary Movies 1–4).
Statistical analysis. Statistical analysis was performed using GraphPad Prism 6 &
7, and the tests used were Student’s t-tests, one-way and two-way ANOVAs with
post-tests and linear regression, as are indicated in ﬁgure legends, all data are
assumed normally distributed and were log transformed where appropriate before
analysis. *P< 0.05, **P< 0.01, ***P< 0.001. Ingenuity pathway analysis (IPA,
Qiagen) was used on metabolomic data sets to identify differences in metabolite
pathways. All error bars represent the mean± the standard error of the mean (SEM
unless stated).
Data availability. The RNA-seq data discussed in this publication have been
deposited in NCBI’s Gene Expression Omnibus72 and are accessible through GEO
Series accession number GSE104920. The metabolomics data are attached as
Supplementary Data 1–2 and all other data are available from the authors upon
request.
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